Research programme: small molecules - Crinetics Pharmaceuticals

Drug Profile

Research programme: small molecules - Crinetics Pharmaceuticals

Alternative Names: CRN02481

Latest Information Update: 25 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crinetics Pharmaceuticals
  • Class Analgesics; Antihypoglycaemics; Small molecules
  • Mechanism of Action Melanocortin-type-2-receptor-antagonists; Somatostatin receptor 5 agonists; Somatostatin receptor subtype 4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hyperinsulinaemia
  • Research Cushing syndrome; Pain

Most Recent Events

  • 21 Jun 2018 Crinetics Pharmaceuticals receives SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institutes of Health (NIH) for CRN 02481 development in congenital hyperinsulinaemia
  • 21 Jun 2018 Preclinical trials in Hyperinsulinaemia in USA (PO)
  • 17 Mar 2018 Pharmacodynamics data from preclinical studies in Hyperinsulinaemia presented at the 100th Annual Meeting of the Endocrine Society (ENDO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top